02.10.2017 • NewsDede WillamsBluestarAsahi Kasei

Asahi Kasei and Bluestar Studying mPPE

(c) mmmx/Shutterstock
(c) mmmx/Shutterstock

Japan’s Asahi Kasei and China’s Bluestar, a ChemChina subsidiary, have agreed to study the economics of building production facilities for producing a modified polyphenylene ether (mPPE) in China.

The facilities would include the intermediates 2,6-xylenol and polyphenylene ether (PPE). Following completion of detailed feasibility studies, the companies plan to make a final investment decision by March 2018.

The plans will be realized by a joint venture agreed in February of this year and will leverage Bluestar’s technology for 2,6-xylenol and PPE in combination with Asahi Kasei’s mPPE compounding technology and applications development capability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read